Skip to main content
SpringerLink
Log in

Plasma cell-free DNA and its DNA integrity as biomarker to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate-specific antigen

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Objectives

To investigate whether plasma cell-free DNA (cfDNA) or its integrity could differentiate prostate cancer from benign prostate hyperplasia (BPH) in patients with serum prostate-specific antigen (PSA) ≥ 4 ng/ml.

Methods

Ninety-six patients with prostate cancer and 112 patients with BPH were enrolled. cfDNA levels in plasma before prostate biopsy were quantified by real-time PCR amplification of ALU gene (product size of 115 bp), and quantitative ratio of ALU (247 bp) to ALU (115 bp) reflected the integrity of cfDNA.

Results

In patients with serum PSA ≥ 4 ng/ml, there were significant differences in plasma cfDNA or its integrity between the patients with prostate cancer (19.74 ± 4.43, 0.34 ± 0.05) and patients with BPH (7.36 ± 1.58, 0.19 ± 0.03; P < 0.001, P < 0.001). Prostate cancer could be differentiated with a sensitivity of 73.2 % and a specificity of 72.7 % by cfDNA (AUC = 0.864). The integrity of cfDNA had a sensitivity of 81.7 % and a specificity of 78.8 % for the distinguishing prostate cancer from BPH (AUC = 0.910).

Conclusions

cfDNA and its integrity could be applied to differentiate prostate cancer from BPH in patients with serum PSA ≥ 4 ng/ml.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300

    Article  PubMed  Google Scholar 

  2. Strope SA, Andriole GL (2010) Prostate cancer screening: current status and future perspectives. Nat Rev Urol 7:487–493

    Article  PubMed  Google Scholar 

  3. Porcaro AB, Migliorini F, Romano M et al (2010) Investigative clinical study on prostate cancer: on the role of the pretreatment total PSA to free testosterone ratio in selecting different biology groups of prostate cancer patients. Int Urol Nephrol 42:673–681

    Article  PubMed  CAS  Google Scholar 

  4. Heijnsdijk EA, der Kinderen A, Wever EM et al (2009) Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer. Br J Cancer 101:1833–1838

    Article  PubMed  CAS  Google Scholar 

  5. Wang BG, Huang HY, Chen YC et al (2003) Increased plasm DNA integrity in cancer patients. Cancer Res 63:3966–3968

    PubMed  CAS  Google Scholar 

  6. Schwarzenbach H, Hoon DS, Pantel K (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11:426–437

    Article  PubMed  CAS  Google Scholar 

  7. Schwarzenbach H, Alix-Panabières C, Müller I et al (2009) Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res 15:1032–1038

    Article  PubMed  CAS  Google Scholar 

  8. Umetani N, Giuliano AE, Hiramatsu SH et al (2006) Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol 24:4270–4276

    Article  PubMed  CAS  Google Scholar 

  9. Gui-Zhong L, Libo M, Guanglin H et al (2011) The correlation of extent and grade of inflammation with serum PSA levels in patients with IV prostatitis. Int Urol Nephrol 43:295–301

    Article  PubMed  Google Scholar 

  10. Heidenreich A, Aus G, Bolla M et al (2008) Eau guidelines on prostate cancer. Eur Urol 53:68–80

    Article  PubMed  Google Scholar 

  11. Strittmatter F, Stieber P, Nagel D et al (2011) Detection of prostate cancer with complexed PSA and complexed/total PSA ratio—is there any advantage? Eur J Med Res 16:445–450

    Article  PubMed  CAS  Google Scholar 

  12. Ellinger J, Wittkamp V, Albers P et al (2009) Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer. J Urol 181:363–371

    Article  PubMed  CAS  Google Scholar 

  13. Kumar S, Guleria R, Singh V et al (2010) Efficacy of circulating plasma DNA as a diagnostic tool for advanced non-small cell lung cancer and its predictive utility for survival and response to chemotherapy. Lung Cancer 70:211–217

    Article  PubMed  Google Scholar 

  14. Gang F, Guorong L, An Z et al (2010) Prediction of clear cell renal cell carcinoma by integrity of cell-free DNA in serum. Urology 75:262–265

    Article  PubMed  Google Scholar 

  15. Wu TL, Zhang D, Chia JH et al (2002) Cell-free DNA: measurement in various carcinomas and establishment of normal reference range. Clin Chim Acta 321:77–87

    Article  PubMed  CAS  Google Scholar 

  16. Papadopoulou E, Davilas E, Sotiriou V et al (2004) Cell-free DNA in plasma as a new molecular marker for prostate cancer. Oncol Res 14:439–445

    PubMed  CAS  Google Scholar 

  17. Altimari A, Grigioni AD, Benedettini E et al (2008) Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer. Am J Clin Pathol 129:756–762

    Article  PubMed  CAS  Google Scholar 

  18. Boddy JL, Gal S, Malone PR et al (2005) Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease. Clin Cancer Res 11:1394–1399

    Article  PubMed  CAS  Google Scholar 

  19. Gordian E, Ramachandran K, Reis IM et al (2010) Serum free circulating DNA is a useful biomarker to distinguish benign versus malignant prostate disease. Cancer Epidemiol Biomarkers Prev 19:1984–1991

    Article  PubMed  CAS  Google Scholar 

  20. Hanley R, Rieger-Christ KM, Canes D et al (2006) DNA integrity assay: a plasma-based screening tool for the detection of prostate cancer. Clin Cancer Res 12:4569–4574

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This research was supported by Yijishan Hospital of Wannan Medical College (WK2011F26 and YR201112).

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Ultrasound, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, China

    Jiang Feng

  2. Department of Urology, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, China

    Huang Houbao

  3. Clinical Genetics Laboratory, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, China

    Feng Gang

  4. Department of Ultrasound, Third Xiangya Hospital of Central-south University, Changsha, Hunan, China

    Xiao Li

  5. Department of Urology, Third Xiangya Hospital of Central-south University, Changsha, Hunan, China

    Tang Jin

  6. Department of Cardiology, Third Xiangya Hospital of Central-south University, Changsha, Hunan, China

    Cao Yu

  7. Department of Urology, North Hospital, CHU of Saint-Etienne, Saint-Étienne, France

    Li Guorong

Authors
  1. Jiang Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Feng Gang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tang Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Huang Houbao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Cao Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Li Guorong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cao Yu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Feng, J., Gang, F., Li, X. et al. Plasma cell-free DNA and its DNA integrity as biomarker to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate-specific antigen. Int Urol Nephrol 45, 1023–1028 (2013). https://doi.org/10.1007/s11255-013-0491-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-013-0491-2

Keywords

Search

Navigation